Final Review | Knowledge Base

Content Status at the final stage of review before it is approved for use.

Quality Assurance of Anti-TB Drugs

H5Content

Prevention of Drug-resistance

H5Content

Newer Anti-TB Drugs: Bedaquiline [Bdq]

H5Content

State Airborne Infection Control [AIC] Committee

H5Content

Management of Hepato-toxicity During Treatment with H Mono/Poly DR-TB Regimen

H5Content

Management of Prolonged QTcF During Treatment with Shorter/Longer Oral MDR-TB Regimen

H5Content

Management of QT Prolongation by Grade of Severity of ADR

H5Content

Eligibility Criteria for the Use of Delamanid [Dlm] in MDR/RR-TB Treatment

H5Content

Drugs Not Included in Groups A - C and Rationale for Non-inclusion

H5Content

Rationale for Grouping of Anti-TB Drugs

H5Content

Subscribe to Final Review